The long term goal of this application by the Ontario Familial Breast Cancer Registry (OFR) is to participate as part of the Breast Cancer Family Registry (BCFR) to establish and maintain a hypothesis-driven research infrastructure capable of: - providing an infrastructure for a broad research agenda in the genetic epidemiology of breast and related cancers that can support a wide spectrum of interdisciplinary and translational projects - identifying and following up a cohort of individuals who span the whole spectrum of breast cancer risk and their families - identifying diverse genetically susceptible populations that could benefit from enrollment in the| preventive and therapeutic interventions - developing an adaptive and evolutionary informatics model to support the BCFR's evolving needs and facilitate cooperative research.
Our specific aims are: a) to continue to maintain and enhance the BCFR, b) to expand families, and c) to take advantage of these resources to address important questions in familial and non-familial breast cancer. To carry out our research agenda as well as to maintain and further enhance the value of the BCFR for our use and that of other investigators, we propose the following core infrastructure components and platforms: 1) follow-up, 2) targeted recruitment and expansion of populations of special interest, 3) clinical, 4) pathology, 5) biospecimens, 6) molecular, 7) analytic/informatics, 8) behavioral/survivorship and 9) administration, travel, and coordination. The OFR proposes a collaborative research agenda to focus on four themes: 1) identification of genetic factors related to breast cancer risk, 2) investigation of environmental modifiers of breast cancer risk, 3) translational and clinical studies and 4) behavioral response to familial breast cancer. The themes form a bi-directional continuum of research from basic biology to clinical practice to address our overriding goal of understanding the causes of breast cancer, developing new strategies for primary prevention, and developing new approaches that will impact on patient care.
|Dite, Gillian S; MacInnis, Robert J; Bickerstaffe, Adrian et al. (2017) Testing for Gene-Environment Interactions Using a Prospective Family Cohort Design: Body Mass Index in Early and Later Adulthood and Risk of Breast Cancer. Am J Epidemiol 185:487-500|
|Barrdahl, Myrto; Rudolph, Anja; Hopper, John L et al. (2017) Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium. Int J Cancer 141:1830-1840|
|Dite, Gillian S; MacInnis, Robert J; Bickerstaffe, Adrian et al. (2016) Breast Cancer Risk Prediction Using Clinical Models and 77 Independent Risk-Associated SNPs for Women Aged Under 50 Years: Australian Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev 25:359-65|
|Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2 (see original citation for additional authors) (2016) No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol 141:386-401|
|Southey, Melissa C (see original citation for additional authors) (2016) PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet 53:800-811|
|Lin, Wei-Yu (see original citation for additional authors) (2015) Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Hum Mol Genet 24:285-98|
|Rudolph, Anja; Milne, Roger L; Truong, Thérèse et al. (2015) Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors. Int J Cancer 136:E685-96|
|Khan, Sofia; Greco, Dario; Michailidou, Kyriaki et al. (2014) MicroRNA related polymorphisms and breast cancer risk. PLoS One 9:e109973|
|Antoniou, Antonis C; Casadei, Silvia; Heikkinen, Tuomas et al. (2014) Breast-cancer risk in families with mutations in PALB2. N Engl J Med 371:497-506|
|Johnson, Nichola; Dudbridge, Frank; Orr, Nick et al. (2014) Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. Breast Cancer Res 16:R51|
Showing the most recent 10 out of 104 publications